[HTML][HTML] Immune checkpoint inhibitors in cancer therapy
The discovery of immune checkpoint proteins such as PD-1/PDL-1 and CTLA-4 represents a
significant breakthrough in the field of cancer immunotherapy. Therefore, humanized …
significant breakthrough in the field of cancer immunotherapy. Therefore, humanized …
Exploring low-dose radiotherapy to overcome radio-immunotherapy resistance
J Wang, J Zhang, W Wen, F Wang, M Wu… - … et Biophysica Acta (BBA …, 2023 - Elsevier
Immune checkpoint inhibitors (ICIs) have revolutionized the current treatment landscape for
cancer, yet the response rates of ICIs remain unmet. Synergistic with immunotherapy, low …
cancer, yet the response rates of ICIs remain unmet. Synergistic with immunotherapy, low …
[HTML][HTML] First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2–directed antibody-drug conjugate Datopotamab …
T Shimizu, J Sands, K Yoh, A Spira… - Journal of Clinical …, 2023 - ncbi.nlm.nih.gov
PURPOSE This first-in-human, dose-escalation and dose-expansion study evaluated the
safety, tolerability, and antitumor activity of datopotamab deruxtecan (Dato-DXd), a novel …
safety, tolerability, and antitumor activity of datopotamab deruxtecan (Dato-DXd), a novel …
[HTML][HTML] Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices
V Velcheti, X Hu, B Piperdi, T Burke - Scientific reports, 2021 - nature.com
Evidence from real-world clinical settings is lacking with regard to first-line immunotherapy
plus chemotherapy for the treatment of non-small cell lung cancer (NSCLC). Our aim was to …
plus chemotherapy for the treatment of non-small cell lung cancer (NSCLC). Our aim was to …
[HTML][HTML] TGF-β-dependent reprogramming of amino acid metabolism induces epithelial–mesenchymal transition in non-small cell lung cancers
F Nakasuka, S Tabata, T Sakamoto… - Communications …, 2021 - nature.com
Abstract Epithelial–mesenchymal transition (EMT)—a fundamental process in
embryogenesis and wound healing—promotes tumor metastasis and resistance to …
embryogenesis and wound healing—promotes tumor metastasis and resistance to …
[HTML][HTML] Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced …
A Ardizzoni, S Azevedo, B Rubio-Viqueira… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Original research: Primary results from TAIL: a global single-arm safety study of
atezolizumab monotherapy in a diverse population of patients with previously treated …
atezolizumab monotherapy in a diverse population of patients with previously treated …
[HTML][HTML] Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology …
E Nadler, B Arondekar, KM Aguilar, J Zhou… - Journal of Cancer …, 2021 - Springer
Purpose Treatments for advanced non-small cell lung cancer (NSCLC) have evolved to
include targeted and immuno-oncology therapies, which have demonstrated clinical benefits …
include targeted and immuno-oncology therapies, which have demonstrated clinical benefits …
[HTML][HTML] Long-term real-world outcomes of first-line pembrolizumab monotherapy for metastatic non-small cell lung cancer with≥ 50% expression of programmed cell …
V Velcheti, X Hu, L Yang, MC Pietanza… - Frontiers in …, 2022 - frontiersin.org
Objectives: Immune checkpoint inhibitors (ICIs) of programmed cell death 1/programmed
cell death ligand 1 (PD-1/PD-L1) have been rapidly adopted in US clinical practice for first …
cell death ligand 1 (PD-1/PD-L1) have been rapidly adopted in US clinical practice for first …
[HTML][HTML] Relationship between nutritional status and clinical outcome in patients treated for lung cancer
J Polański, M Chabowski, N Świątoniowska-Lonc… - Nutrients, 2021 - mdpi.com
Background. Between 34.5% and 69% of the patients with lung cancer are at risk of
malnutrition. Quality of life (QoL) and physical status assessment provides valuable …
malnutrition. Quality of life (QoL) and physical status assessment provides valuable …
[HTML][HTML] Tumor-derived exosomal miR-620 as a diagnostic biomarker in non-small-cell lung cancer
Y Tang, Z Zhang, X Song, M Yu, L Niu, Y Zhao… - Journal of …, 2020 - hindawi.com
Background. Evidence has suggested the functional role of exosomal miRNAs in cancer
diagnosis. This study aimed to determine whether the serum exosomal biomarkers can …
diagnosis. This study aimed to determine whether the serum exosomal biomarkers can …